Summary:
The purpose of this study is to see how CIN-107 works in treating rHTN. CIN-107 will be compared to placebo. A placebo looks like the study drug but does not contain any medication (active ingredient). Researchers use a placebo to see if a study drug works better or is safer than not taking anything at all.
The drug being studied in this research, CIN-107, blocks an enzyme called aldosterone synthase. This reduces aldosterone levels and may help lower blood pressure and help slow down heart, kidney, and blood vessel damage.
Qualified Participants Must:
• At least 18 years of age
•
Have blood pressure readings above or equal to 140/80
•
Must be taking at least 3 medications for blood pressure, including a diuretic
Qualified Participants May Receive:
- Compensation for time and travel expenses
- Study related procedures such as blood work and ECG
- Physical performed by a board certified physician